Key Highlights
- SELLAS Life Sciences was trading up 15.19% at USD 9.25 in pre-market on Friday, November 13, 2026, in pre-market market data, with no company announcement dated November 11 to 13 found.
- The Phase 3 REGAL trial reached its pre-specified 80th overall survival event on October 28, 2026, triggering the final analysis, and a published report put the stock's drop that day at 18%.
- Preliminary topline results for galinpepimut-S, a WT1-targeting immunotherapy for acute myeloid leukemia in second remission, are expected this quarter, with no specific date given.
- Cash and equivalents were USD 138.3 million at June 30, 2026, and shares outstanding were about 201.95 million in market data, which values the stock near USD 1.87 billion at USD 9.25 (calculated).
Rebound After the 80th Event Sell-Off
SELLAS Life Sciences (NASDAQ:SLS) was quoted at USD 9.25 in pre-market on Friday, November 13, 2026, up 15.19% from a prior close implied near USD 8.03 (calculated). No press release, filing or analyst action dated November 11 to November 13 was found. On October 28 the company said REGAL had reached its 80th event, which triggers database lock, unblinding and analysis of the primary endpoint, overall survival. The stock fell that day, one report citing 18% and another a close of USD 10.38, down 14.71%. A rebound can follow such a drop with no news behind it, and the quote of USD 9.25 is still below the USD 10.38 close that followed the milestone news.
What REGAL Tests and When Data Are Due
REGAL is a randomized registrational study of galinpepimut-S as maintenance therapy in adults with acute myeloid leukemia in second complete remission. The product is licensed from Memorial Sloan Kettering Cancer Center. Because the study is event-driven, the 80th death set the timing of the analysis. The company plans to announce preliminary topline results this quarter, which means by December 31, 2026, and it has said it will also present SLS009 combination data in high-risk AML at the 2026 American Society of Hematology meeting. The December 14 date for that presentation comes from published coverage. The company also develops SLS009, a CDK9 inhibitor, so the stock reflects two programs, with GPS carrying most of the near-term weight.
Binary Risk, Cash and the Dilution Question
A single readout can lift or cut the valuation sharply, and the fall after the milestone shows holders did not treat it as a certain win. Cash of USD 138.3 million at June 30 compares with a net loss of about USD 32.5 million in market data, though the period for that loss is unclear, so the cash runway cannot be stated. Positive data could prompt a Capital raise, and negative data could threaten the program. The 52-week range is USD 1.39 to USD 15.88, and quoted pre-market moves can reverse. A year-to-date gain of about 128% as of November 10 in recent coverage means expectations are already high into the readout.
Where Things Stand
No identifiable news explains the 15.19% pre-market gain in SELLAS Life Sciences (NASDAQ:SLS), which looks like a rebound after the October 28 sell-off and positioning ahead of the REGAL readout. The USD 9.25 quote is pre-market only. The evidence is balanced because the milestone has been reached but results are unknown. Watch for the topline announcement expected this quarter, the SLS009 presentation in December, the third-quarter report and any financing after data.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...